Literature DB >> 6801096

A double-blind controlled trial of lithium carbonate primary anorexia nervosa.

H A Gross, M H Ebert, V B Faden, S C Goldberg, L E Nee, W H Kaye.   

Abstract

In this 4-week, double-blind, parallel group study, eight young women with primary anorexia nervosa were evaluated on lithium carbonate, and eight patients were treated with placebo and served as a control. All patients participated in a behavior modification treatment program. The lithium-treated and placebo groups were comparable on nearly all findings measured at baseline (t tests), with no significant differences observed except for calories per day, percent fat composition of the daily calories, "interpersonal sensitivity" on the Hopkins Symptom Checklist-90 (HSCL-90), "self-care" on the Goldberg Anorectic Attitude Questionnaires, (GAAQ) and "manipulation of others" on the physician-rated Psychiatric Rating Scale (PRS). The data were analyzed using repeated measures analysis of covariance (ANCOVA) with the baseline measure as the covariate. Group differences appeared in the areas of "denial or minimization of illness" on the GAAQ, "selective appetite" on the PRS, and weight. Although the repeated measures ANCOVA for weight revealed a significant group-by-time interaction, indicating nonparallelism and invalidating the test for group differences, ANCOVAs performed for each individual time point showed greater weight gain in the lithium group at weeks 3 and 4.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6801096     DOI: 10.1097/00004714-198111000-00005

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  7 in total

Review 1.  Psychopharmacotherapy of anorexia nervosa, bulimia nervosa and binge-eating disorder.

Authors:  S Krüger; S H Kennedy
Journal:  J Psychiatry Neurosci       Date:  2000-11       Impact factor: 6.186

Review 2.  The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects.

Authors:  Guido K W Frank; Megan E Shott
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

Review 3.  The psychopharmacotherapy of anorexia nervosa: clinical, neuroendocrine and metabolic aspects.

Authors:  G Abbate Daga; L Gianotti; V Mondelli; R Quartesan; S Fassino
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

Review 4.  Current perspectives on drug therapies for anorexia nervosa and bulimia nervosa.

Authors:  S H Kennedy; D S Goldbloom
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

5.  Advances in the Treatment of Anorexia Nervosa and Bulimia Nervosa.

Authors:  S H Kennedy; D S Goldbloom
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

Review 6.  Rational therapy of eating disorders.

Authors:  S J Crow; J E Mitchell
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

7.  Current treatment for anorexia nervosa: efficacy, safety, and adherence.

Authors:  Lindsay P Bodell; Pamela K Keel
Journal:  Psychol Res Behav Manag       Date:  2010-10-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.